Compare Citius Pharmaceuticals Inc (CTXR) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Williams Companies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Williams Companies Inc trades at $72.45 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 6496.3× Citius Pharmaceuticals Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Williams Companies Inc for 58 Days on average.
| CTXR | WMB | |
|---|---|---|
Market Cap | $13.62M | $88.48B |
Volume | 132,438 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $1.82 | $79.40 |
52-Week Low | $0.48 | $56.51 |
Typical Hold Time | 16 Days | 58 Days |
Enterprise Value | $3.79M | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Williams Companies (WMB) trades at $71.46, down 1.28% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with 25.18% net income margin and 24.02% ROE, though recent earnings have been mixed with two misses and one beat. Analyst consensus is strongly bullish with 79% buy ratings and an $87.27 price target, representing 22% upside. Recent news highlights WMB's positioning to benefit from AI-driven natural gas demand growth.
WMB offers compelling value with strong cash flow generation and dividend growth potential, though investors face risks from energy market volatility and high debt levels. The company's fee-based revenue model provides stability, while strategic acquisitions like Momentum Midstream enhance growth prospects. Current valuation at 28.82 P/E appears reasonable given the growth trajectory and defensive characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
